# Contact Chai Peptides — Editorial Desk

> Reach the Chai Peptides editorial desk regarding citations, corrections, or research-related correspondence about our Metabolic & Weight Research peptide digest.

Correspondence on citations, corrections, and newly published research — the kind of message a reference desk exists to receive.

## Editorial correspondence

Chai Peptides welcomes correspondence on the research record: a citation quoted inaccurately, a newly published trial, a regulatory update that changes an approval status, or a peer-reviewed study on MOTS-c, tesamorelin, or tirzepatide that belongs on the [references page](/references). This is the most useful class of message this desk receives, and each one is read carefully.

The most actionable submissions specify the page in question, the exact passage being challenged, and the supporting source — a DOI or PubMed identifier wherever possible — so a proposed correction can be checked against its source before anything changes.

**Editorial mailbox:** editors@chaipeptides.com

## What this desk cannot do

So that no message goes unanswered for the wrong reason: Chai Peptides is a literature digest, not a clinical service, so it cannot advise on or recommend human use of MOTS-c, tesamorelin, or tirzepatide; suggest a dose, schedule, or route of administration for any individual; evaluate whether a cited finding applies to someone's specific situation; or help source, sell, or locate any compound from any supplier. Tesamorelin and tirzepatide are prescription medicines available only through a licensed provider; MOTS-c has no approved human use of any kind and no established human dosing in the literature. Readers seeking medical guidance should consult a licensed clinician in their jurisdiction. Responses to editorial correspondence are not guaranteed and may be delayed.

---

An independent, citation-first read of the metabolic and weight-research literature — enthusiasm always chased with a caveat, never with a diagnosis or a dose.